摘要：
The U.S. Food and Drug Administration today approved Inflectra (infliximab-dyyb) for multiple indications. Inflectra is administered by intravenous infusion. This is the second biosimilar approved by the FDA.
Supporting:
http://www.fda.gov. Information from US FDA[J]. 中国药学(英文版), 2016, 25(4): 318-320.
http://www.fda.gov. Information from US FDA[J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(4): 318-320.
>
>